Table 1.
Baseline clinical characteristics and outcomes of the pMN patients investigated in this study
| Parameters | n (%) or median (IQR) (n = 111) |
|---|---|
| Sex, male/female | 68 (61.3)/43 (38.7) |
| Age, years | 57 (41–66) |
| Diabetes, n (%) | 13 (11.7) |
| Hypertension, n (%) | 55 (49.5) |
| Systolic blood pressure, mmHg | 132.0 (123.0–140.0) |
| Diastolic blood pressure, mmHg | 80.0 (720–85.0) |
| Albumin, g/L | 26.0 (23.0–29.0) |
| Serum creatinine, μmol/L | 67.0 (56.0–80.0) |
| eGFR, mL/min/1.73 m2 | 99.2 (85.9–114.6) |
| CKD stage, n (%) | |
| 1 | 77 (69.4) |
| 2 | 28 (25.2) |
| 3 | 6 (5.4) |
| sPLA2R-Ab positive, n (%) | 81 (73.0) |
| Levels of sPLA2R-Ab, RU/mL | 85.9 (10.8–349.0) |
| Hemoglobin, g/L | 132.0 (119.0–144.0) |
| Serum IgG, mg/dL | 601 (433.5–738.0) |
| Total cholesterol, mmol/L | 7.2 (6.1–8.5) |
| Triglyceride, mmol/L | 2.3 (1.5–3.2) |
| HDL-C, mmol/L | 1.2 (1.1–1.6) |
| LDL-C, mmol/L | 4.5 (3.8–5.7) |
| Proteinuria, g/24 h | 5.7 (4.5–7.2) |
| Urinary IgG/Cr, mg/g | 14.7 (8.7–29.1) |
| Urinary Tf, mg/g | 2.2 (1.3–4.0) |
| Urinary α1m/Cr, mg/mg | 307.5 (207.7–469.9) |
| Urinary NAG/Cr, U/g | 38.6 ± 18.6 |
| Kidney pathology, n (%) | |
| IF IgG (+) | 111 (100) |
| IF IgA (+) | 18 (16.2) |
| IF IgM (+) | 32 (28.8) |
| IF C3 (+) | 93 (83.8) |
| IF C1q (+) | 25 (22.5) |
| MN stage, n (%) | |
| I | 51 (45.9) |
| II | 45 (40.5) |
| III | 6 (5.4) |
| Obsolescent glomeruli, % | 2.1 (0–6.7) |
| Focal segmental glomerular sclerosis, n (%) | 20 (18.0) |
| Acute tubular injury, n (%) | 23 (20.7) |
| Tubular atrophy | |
| Stage 0 | 93 (83.8) |
| Stage 1 | 18 (16.2) |
| Interstitial fibrosis | |
| Stage 0 | 92 (82.9) |
| Stage 1 | 19 (17.1) |
| Vascular hyalinosis, n (%) | 54 (48.65) |
| Immunosuppressive therapy, n (%) | 79 (71.2) |
| Complete remission, n (%) | 59 (53.2) |
| Partial remission, n (%) | 31 (27.9) |
| Progression, n (%) | 21 (18.9) |
| ESRD, n (%) | 11 (9.9) |
| Follow-up time, months | 40.0 (25.0–58.0) |
CKD chronic kidney disease, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease, HDL-C high-density lipoprotein cholesterol, IF immunofluorescence IQR interquartile range, LDL-C low-density lipoprotein cholesterol, α1m α1-microglobulin, MN membranous nephropathy, NAG N-acetyl-β-d-glucosaminidase, sPLA2R-Ab serum phospholipase A2 receptor antibody, Tf transferrin